ArisGlobal LifeSphere Consulting & Integration for Pharma

ArisGlobal LifeSphere is a unified, AI-first life sciences platform that spans pharmacovigilance, regulatory affairs, clinical operations, quality, and medical affairs. Founded in 1987 and headquartered in Miami, ArisGlobal has positioned LifeSphere as the industry's most AI-forward alternative to competing platforms like Oracle Argus Safety and Veeva Vault Safety. The platform is organized into domain-specific clouds — LifeSphere Safety (including MultiVigilance, Advanced Intake, Literature Intelligence, and Advanced Signals), LifeSphere Regulatory (RIM, Submissions, Labeling, Product Compliance, Regulatory Analytics), LifeSphere Clinical, LifeSphere Quality, and LifeSphere Medical Affairs. Pharmaceutical companies choose LifeSphere for three primary reasons: its embedded NavaX cognitive computing engine that applies generative and agentic AI natively across every module; its unified data model that reduces integration overhead between safety, regulatory, and clinical functions; and its pharma-specific design built around ICH guidelines, EudraVigilance, FDA FAERS, and global health authority expectations. IntuitionLabs helps pharmaceutical clients implement, configure, integrate, validate, and AI-enhance LifeSphere deployments.

NavaX is ArisGlobal's next-generation cognitive computing engine that weaves generative AI and agentic AI directly into the LifeSphere platform, rather than treating AI as an optional add-on. ArisGlobal reports that NavaX drives up to 65% efficiency gains in case intake, 90% data extraction accuracy, 50% efficiency improvements across safety and regulatory workflows, and saves 100+ hours on manual regulatory workflow tasks. Unlike bolt-on AI tools that sit beside a pharmacovigilance database, NavaX is designed to perform end-to-end autonomous reasoning — it can interpret regulatory guidelines, convert them into structured rule checklists, validate dossiers, generate narratives, detect safety signals, and orchestrate multi-step workflows. The platform currently processes more than 1 million safety cases and is projected to reach 2.5 million cases by mid-2026, with public performance metrics demonstrating data accuracy greater than 95%. Compared to Oracle's Safety One Intake, which focuses primarily on document-to-field extraction, NavaX extends further into narrative generation, signal reasoning, translation, and regulatory intelligence. IntuitionLabs helps clients configure NavaX extraction rules, validate AI accuracy against manual benchmarks, and extend the native capabilities with custom workflows that encode organization-specific business logic and medical writing conventions.

LifeSphere Safety is ArisGlobal's flagship pharmacovigilance suite and comprises several interlocking modules. LifeSphere MultiVigilance is the core case management system, processing individual case safety reports from intake through regulatory submission in ICH E2B(R3) format. LifeSphere Advanced Intake uses NavaX to automate extraction from MedWatch forms, CIOMS reports, clinical trial SAE forms, and unstructured narratives, reportedly eliminating a majority of manual data entry. LifeSphere Literature Intelligence automates medical literature surveillance across PubMed, Embase, and other databases per EMA GVP Module VI requirements. LifeSphere Advanced Signals delivers statistical disproportionality analysis (PRR, ROR, MGPS) plus narrative-based AI pattern detection. NavaX Translation, launched in 2026, embeds certified pharma-grade translation into Safety workflows for multilingual case processing. The modules share a unified data model so that a single adverse event report flows seamlessly from intake through signal detection without the brittle integration layers that characterize legacy pharmacovigilance architectures. IntuitionLabs helps pharmaceutical clients map current-state workflows to the appropriate LifeSphere Safety modules and design integration touch points with clinical trial systems, regulatory submission gateways, and enterprise reporting layers.

LifeSphere Regulatory integrates data, content, and processes across the full regulatory lifecycle, competing directly with Veeva Vault RIM. The suite includes LifeSphere RIM for regulatory information management — tracking product registrations, health authority commitments, and submission history across global markets; LifeSphere Submissions for authoring and publishing electronic Common Technical Document (eCTD) submissions to the FDA, EMA, and other health authorities; LifeSphere Labeling for structured product labeling management aligned with FDA SPL requirements; LifeSphere Product Compliance for IDMP (ISO Identification of Medicinal Products) and xEVMPD compliance; and LifeSphere Regulatory Analytics for portfolio-level reporting. New 2026 Intelligence Agents automatically interpret regulatory guidelines, convert them into rule checklists, and assess dossiers with compliance evaluations, while Distribution Agents continuously validate evolving guidelines against internal distribution logic. IntuitionLabs implements LifeSphere Regulatory, migrates data from legacy RIM systems, configures health authority submission templates, and builds AI agents that augment the native NavaX capabilities with client-specific regulatory intelligence.

ArisGlobal LifeSphere, Oracle Argus Safety, and Veeva Vault Safety are the three dominant platforms in life sciences pharmacovigilance. Oracle Argus has the largest installed base, a two-decade track record, and deep integration with Oracle Empirica for signal detection — it is the safest default for organizations with established PV operations. Veeva Vault Safety is the newest entrant and appeals to organizations already standardized on the Veeva Vault platform for regulatory, quality, and clinical document management, offering unified document and case management. ArisGlobal LifeSphere's differentiator is its AI-first positioning: NavaX is more deeply embedded across the platform than competing AI layers, and ArisGlobal has been aggressively rolling out new agent capabilities in 2025-2026. LifeSphere also covers a broader functional footprint than either competitor, spanning safety, regulatory, clinical, quality, and medical affairs in a single platform. The right choice depends on existing technology investments, integration requirements, CRO preferences, the degree of AI adoption the organization wants to pursue, and specific functional needs around signal management, aggregate reporting, and regulatory submission scale. IntuitionLabs is platform-neutral and helps clients evaluate these options based on their actual operational context rather than vendor marketing claims.

ICH E2B(R3) is the current international standard for electronic transmission of Individual Case Safety Reports (ICSRs), replacing the older E2B(R2) format. The standard, adopted by the FDA FAERS, EMA EudraVigilance, Japan PMDA, and Health Canada, uses an XML message structure that captures structured case data with standardized MedDRA terminology and WHO Drug Dictionary coding. LifeSphere MultiVigilance generates and transmits E2B(R3) reports natively, with a submission rules engine that determines expedited versus periodic reporting obligations based on case characteristics, country of occurrence, and marketing authorization status. The system handles the full lifecycle: initial submissions, follow-up reports, nullification messages, and acknowledgment reconciliation with health authority gateways. For organizations migrating from E2B(R2), IntuitionLabs manages the transition project including gap analysis, data mapping, validation of the upgraded submission rules, and end-to-end testing with health authority acceptance portals. The transition is particularly complex for multinational pharmaceutical companies that must maintain parallel E2B(R2) and E2B(R3) capabilities during phased rollout across different health authorities.

A typical LifeSphere Safety implementation for a mid-sized pharmaceutical company spans four to nine months depending on product portfolio size, regulatory scope, and integration complexity. Phase 1: Discovery and Requirements (3-5 weeks) — mapping current pharmacovigilance workflows, health authority obligations across all markets, product portfolio, MedDRA/WHO Drug version choices, and integration requirements with clinical and enterprise systems. Phase 2: Configuration (7-12 weeks) — enterprise setup, product registration, case processing workflows, regulatory submission rules for FDA, EMA GVP, PMDA, and other applicable authorities, report templates (MedWatch 3500A, CIOMS I/II), and NavaX AI configuration including extraction rules and confidence thresholds. Phase 3: Integration (4-10 weeks) — building and testing interfaces with EDC safety gateways, regulatory submission gateways, signal detection, document management (Veeva Vault, SharePoint), and enterprise reporting. Phase 4: Validation (4-8 weeks) — executing IQ/OQ/PQ protocols per GAMP 5 guidelines, 21 CFR Part 11 compliance verification, and creation of validation summary reports. Phase 5: Training and Go-Live (3-5 weeks) — role-based training for safety associates, medical reviewers, QA, and IT support, with hypercare support during the initial production period. Full multi-cloud implementations (Safety + RIM + Clinical) typically double those timelines.

LifeSphere exposes REST APIs and supports bidirectional integration with the broader life sciences technology ecosystem. The most common integration patterns we implement include: EDC to LifeSphere Safety for SAE transmission from Medidata Rave, Oracle Clinical One, and Veeva Vault CDMS using ICH E2B(R3) formatted safety messages. LifeSphere to Veeva Vault for document management — case narratives, medical assessments, submission dossiers, and regulatory correspondence stored in Vault with metadata links to LifeSphere records. LifeSphere RIM to SAP ERP for product master data synchronization covering manufacturing site registrations, product identifiers, and supply chain visibility. LifeSphere Clinical to CTMS (Veeva Vault CTMS, Medidata CTMS) for study planning, site management, and monitoring activities. LifeSphere to enterprise reporting via Snowflake or Databricks data warehouses for portfolio-level safety and regulatory analytics. IntuitionLabs builds these integrations using LifeSphere APIs with full validation documentation per GAMP 5 Category 5 guidelines and compliance controls including audit trails, data integrity checks, and role-based access enforcement aligned with 21 CFR Part 11 requirements.

Yes — LifeSphere Safety includes dedicated capabilities for the periodic aggregate reports required by pharmacovigilance regulations worldwide. The ICH E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER), which replaced the older Periodic Safety Update Report (PSUR) in most jurisdictions, and the Development Safety Update Report (DSUR) for clinical trials are all supported through configurable data extraction, line listings, summary tabulations, and narrative authoring workflows. Cases across configurable time periods can be filtered by product, indication, reporter type, seriousness criteria, and geographic region, with exports formatted for inclusion in regulatory report appendices. For FDA NDA/BLA Annual Reports and EMA PSUR submissions, LifeSphere data feeds directly into authoring tools used by pharmacovigilance physicians. NavaX AI can draft preliminary benefit-risk narrative sections from the aggregated case data, giving physicians a substantive starting point rather than a blank page. IntuitionLabs configures LifeSphere aggregate reporting queries, automates data extraction workflows, and builds custom AI narrative drafters tuned to the organization's medical writing style for PBRER, PSUR, and DSUR sections.

Contract research organizations use LifeSphere multi-enterprise configurations to process safety cases and manage regulatory submissions on behalf of multiple pharmaceutical sponsor clients. Each enterprise within the LifeSphere instance maintains separate product registrations, regulatory submission rules, case processing workflows, user access permissions, and reporting configurations — ensuring complete data segregation between sponsors as required by contractual and regulatory obligations. Different sponsors may specify different MedDRA versions, different case processing timelines (some want all non-serious events processed within 10 business days, others within 15), different narrative templates, and different health authority submission routing. NavaX Advanced Intake extends multi-tenancy to AI-powered processing, allowing CROs to configure client-specific extraction rules and accuracy thresholds. This architecture is critical because pharmacovigilance regulatory responsibility ultimately rests with the Marketing Authorization Holder (the sponsor), meaning the CRO must demonstrate that each client's data and processes are managed independently even though they share the same platform. IntuitionLabs configures multi-enterprise LifeSphere deployments for CROs, designs enterprise-specific workflows, and validates the data segregation controls that regulatory inspectors examine during pharmacovigilance inspections.

LifeSphere Clinical is ArisGlobal's clinical operations suite that manages clinical trial safety reporting, investigator notifications, and study-level safety oversight. The platform tightly integrates with LifeSphere Safety so that Suspected Unexpected Serious Adverse Reactions (SUSARs) and other reportable clinical trial safety events flow directly into the pharmacovigilance workflow. Key capabilities include structured SUSAR reporting per ICH E2A timelines (7 days fatal/life-threatening, 15 days other serious), investigator site letter generation for blinded and unblinded notifications, Development Safety Update Report (DSUR) authoring support, clinical trial registration obligations tracking against ClinicalTrials.gov and EU CTIS (Clinical Trials Information System), and protocol-level safety reconciliation between EDC and safety databases. For sponsors running global studies, the platform supports country-specific safety reporting variations including EMA, FDA, PMDA, and national competent authority requirements. IntuitionLabs implements LifeSphere Clinical for emerging biotech companies running their first pivotal trials and for large pharmaceutical sponsors modernizing their clinical safety operations alongside LifeSphere Safety deployment.

Safety database migration is one of our most common ArisGlobal LifeSphere engagements. Organizations migrate to LifeSphere from Oracle Argus Safety, Clintrace, ArisGlobal's legacy ARISg system, custom-built Access/Oracle databases, and earlier LifeSphere versions. Safety data migration is uniquely complex because pharmacovigilance data has long regulatory retention requirements — most jurisdictions require that safety case data be retained for the lifetime of the product plus 10-15 years, and migrated data must maintain its regulatory integrity including audit trails, electronic signatures, and the ability to reproduce any historical regulatory submission exactly as originally transmitted. Our migration approach follows a validated methodology: field-by-field data mapping, MedDRA version reconciliation, drug coding translation between WHO Drug Dictionary versions, migration scripting with built-in data quality checks, pre-defined validation test cases that verify data integrity post-migration, and regulatory continuity verification ensuring migrated cases retain their original receipt date and processing history. The entire effort is governed by a Migration Validation Protocol aligned with FDA data integrity expectations and MHRA data integrity guidance.

Pharmacovigilance regulatory reporting operates under strict timelines defined by health authorities worldwide, and LifeSphere includes a built-in reporting rules engine that automatically determines submission obligations. Expedited reporting (fatal/life-threatening): 7 calendar days for initial submission to the FDA and most health authorities, with follow-up within 8 additional days. Expedited reporting (serious): 15 calendar days for serious, unexpected adverse reactions. Periodic reporting: PBRER/PSUR submission intervals per EU pharmacovigilance legislation (typically every 6 months for the first 2 years post-approval, annually for the next 3 years, then every 3 years). Clinical trial SUSAR reporting: 7 or 15 days per ICH E2A. DSUR annual submission for active clinical programs. LifeSphere tracks these deadlines with configurable alerting, escalates overdue cases to management, and generates compliance metrics dashboards showing on-time submission rates by health authority, product, and case type. Missing a regulatory reporting deadline can result in FDA warning letters, EMA sanctions, or clinical trial suspension. IntuitionLabs configures LifeSphere reporting rules to your complete regulatory obligation matrix.

LifeSphere Medical Affairs enables automation and information flow between medical affairs functions and adjacent regulatory and safety operations. The module supports medical information request management — inquiries from healthcare professionals and patients about approved products that must be logged, responded to, and tracked for quality and compliance. When a medical information inquiry contains an adverse event mention, the system automatically triggers a reportable pharmacovigilance case in LifeSphere Safety, eliminating the manual handoffs that frequently cause compliance gaps in traditional call center architectures. The platform also supports standard response document management, medical science liaison activity tracking, scientific communication planning, and publication tracking aligned with ISMPP good publication practices. Advisory board management and investigator-initiated study tracking round out the typical medical affairs operational footprint. For medical affairs leaders, the integration with LifeSphere Safety is a compelling advantage over standalone medical information platforms because it closes the gap between inquiry intake and adverse event reporting that is a frequent finding during pharmacovigilance inspections. IntuitionLabs implements LifeSphere Medical Affairs alongside Safety deployments and builds AI enhancements for medical information response drafting.

IntuitionLabs is an AI-first life sciences consulting firm founded in 2023 specializing in the implementation, integration, validation, and AI-enhancement of enterprise software for pharmaceutical and biotech organizations. We are not an ArisGlobal reseller or partner — we are an independent consulting firm that helps clients get maximum value from their LifeSphere investment, whether that means a greenfield deployment, migration from a legacy safety database, addition of new LifeSphere modules, integration with Veeva Vault and enterprise systems, validation of NavaX AI components, or ongoing managed services. Our differentiators are threefold. First, deep pharmacovigilance and regulatory domain expertise — our team understands MedDRA, E2B(R3), GVP modules, and PV case processing, not just system integration. Second, AI engineering capabilities — we build custom AI agents, Model Context Protocol (MCP) servers, and automated workflows that extend NavaX with organization-specific intelligence. Third, regulated-industry DNA — our validation team produces audit-ready documentation per GAMP 5, 21 CFR Part 11, and EU Annex 11.